New treatment for tendon disorders using microRNA
miRNA drug for tendinopathy
This study is testing a new treatment using a special molecule to help heal painful tendon issues, especially for older adults, and if it works well in animals, it could eventually be available for people like you who are dealing with tendinopathy.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York/r&d/ctr/translational Med/ther NIH-funded |
| Lab location | 1 site (New Rochelle, UNITED STATES) |
| Project ID | NIH-10884445 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for tendinopathy, a common tendon disorder that causes pain and impaired function, especially in older adults. The approach involves using a specific microRNA, miR-221-5p, which has shown promise in preliminary studies for reducing inflammation and promoting healing in tendon tissues. The research will test this microRNA in animal models to determine its effectiveness and safety, with the goal of eventually obtaining FDA approval for its use in humans. If successful, this treatment could provide a much-needed solution for those suffering from tendinopathy.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults suffering from tendinopathy or chronic tendon pain.
Not a fit: Patients with acute tendon injuries or those not experiencing symptoms of tendinopathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment for tendinopathy, improving quality of life for patients with this condition.
How similar studies have performed: Other studies have shown promise in using microRNA therapies for various conditions, suggesting potential success for this novel approach in treating tendinopathy.
Where this research is happening
New Rochelle, UNITED STATES
- New York/r&d/ctr/translational Med/ther — New Rochelle, United States (Active)
Researchers
- Principal investigator: Fung, David T — New York/r&d/ctr/translational Med/ther
- Study coordinator: Fung, David T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.